A team of researchers from Brigham and Women’s Hospital, Harvard University, and the University of Massachusetts Medical School has designed a convection-enhanced macroencapsulation device (ceMED) that could significantly improve β cell replacement therapies to help many T1D patients.
The 3D geometry of the capsule enables transplanted, insulin secreting β islet cells encapsulated in the cartridge to continuously bathe in nutrients, improving the number of cells that can be accommodated in each capsule and increasing their survival, glucose sensitivity, and insulin secretion.
